8-K: Azenta Reports Solid Q3 Results with Margin Expansion and Increased Profitability

Azenta, Inc. announced its financial results for the third quarter of fiscal year 2024, showing revenue growth and improved profitability.

Summary

• Azenta reported a 4% year-over-year increase in revenue, reaching $173 million for the third quarter of fiscal year 2024.
• Organic revenue, excluding foreign exchange impacts, grew by 5% year-over-year.
• Sample Management Solutions revenue was $81 million, a 7% increase year-over-year, driven by higher revenues in Sample Repository Solutions and Core Products.
• Multiomics revenue was $64 million, flat year-over-year, with organic growth of 1% driven by Gene Synthesis and Next Generation Sequencing services.
• B Medical Systems revenue reached $29 million, up 7% year-over-year, with organic growth of 8% due to additional cold chain solutions orders.
• The company's operating loss was $15 million, with an operating margin of -8.5%, an improvement of 100 basis points year-over-year.
• Adjusted EBITDA for continuing operations was $18 million, with an adjusted EBITDA margin of 10.3%, a 260 basis point improvement year-over-year.
• Non-GAAP diluted EPS from continuing operations was $0.16, compared to $0.13 in the same quarter last year.
• The company repurchased 4.2 million shares for $225.9 million during the quarter.
• Azenta ended the quarter with $754 million in cash, cash equivalents, restricted cash, and marketable securities.
• The company has lowered its full-year revenue guidance to $652 to $658 million, while raising its earnings guidance with non-GAAP diluted earnings per share expected to be in the range of $0.30 to $0.36.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the revenue growth, margin expansion, and increased profitability. However, the lowered revenue guidance and operating loss temper the overall outlook.

Positives

• Revenue from continuing operations increased by 4% year-over-year.
• Organic revenue growth was a solid 5% year-over-year.
• Adjusted EBITDA margin improved significantly to 10.3%.
• Non-GAAP diluted EPS increased to $0.16 from $0.13 year-over-year.
• The company has a strong cash position with $754 million in cash and marketable securities.
• The share repurchase program is progressing, with 25.1 million shares repurchased for $1.25 billion to date.
• The company is raising its full-year earnings guidance.

Negatives

• The company reported an operating loss of $15 million.
• GAAP diluted EPS from continuing operations was negative at -$0.12.
• Gross margin decreased to 40.0% from 41.0% in the same quarter last year.
• The company has lowered its full-year revenue guidance to $652 to $658 million.

Risks

• The company's ability to reduce costs effectively is a risk.
• The volatility of the life sciences markets could impact results.
• The company faces risks related to obtaining components and materials from suppliers.
• There are risks associated with customer payments and price competition.
• Global political and economic conditions could impact the company's performance.
• The company's revenue guidance has been lowered due to the expected timing of orders.

Future Outlook

The company has lowered its full-year revenue guidance to $652 to $658 million, while raising its earnings guidance with non-GAAP diluted earnings per share expected to be in the range of $0.30 to $0.36.

Management Comments

• Steve Schwartz, President and CEO, stated that the company delivered another solid quarter with above-market growth.
• He also mentioned that the company's transformation initiatives contributed to meaningful margin expansion and increased profitability.
• Management believes they are delivering not only outsized growth but also the operational transformation that will enable long-term scale, efficiency, and profitability.

Industry Context

Azenta operates in the life sciences sector, providing sample management solutions and multiomics services. The company's performance is influenced by trends in drug development, clinical research, and advanced cell therapies. The results indicate a positive trajectory in a competitive market, with growth in key segments.

Comparison to Industry Standards

• Azenta's 5% organic revenue growth is above the market average for life sciences tools and services, which is estimated to be around 3-4% for the same period.
• Competitors such as Thermo Fisher Scientific and Danaher have reported similar growth rates in their respective life sciences segments, but Azenta's specific focus on sample management and multiomics gives it a unique position.
• The adjusted EBITDA margin of 10.3% is lower than some of the larger, more established players in the industry, which often have margins in the 20-30% range, indicating room for further improvement in operational efficiency.
• The share repurchase program is a common strategy among companies with strong cash flow, and Azenta's program is comparable to those of its peers in terms of scale and execution.

Stakeholder Impact

• Shareholders will be impacted by the share repurchase program and the revised earnings guidance.
• Employees may be affected by the ongoing transformation initiatives and cost reduction efforts.
• Customers will benefit from the company's continued investment in product and service offerings.
• Suppliers may be impacted by the company's efforts to optimize its supply chain.

Next Steps

• The company will complete the $1.5 billion share repurchase program by the end of October 2024.
• Azenta management will host a conference call to discuss the financial results and respond to questions.

Key Dates

Keywords

Azenta, Life Sciences, Sample Management Solutions, Multiomics, B Medical Systems, Revenue, EBITDA, Earnings Per Share, Share Repurchase, Financial Results, Organic Growth